Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer

Peng Lee, Daniel G. Rosen, Changcheng Zhu, Elvio G. Silva, Jinsong Liu

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Objective. Receptors for estrogen (ER), progesterone (PR), or androgen (AR) are predictive and prognostic markers of malignancy of multiple endocrine organs, including endometrial and breast cancer. However, the role of ERs, PRs, or ARs in the carcinogenesis of ovarian cancer, another sex hormone-dependent malignancy, is still controversial despite numerous studies that have attempted to determine their role. The disagreement in the findings may result from the fact that the numbers of tumor samples in studies have been small and that different immunohistochemical methods have been used that can introduce variation in the scoring of the histology. We therefore examined the pattern of expression of ERs, PRs, and ARs in a large number of samples of primary ovarian carcinoma by using a tissue microarray technique. Methods. We constructed a tissue microarray with 322 samples of primary ovarian carcinoma obtained at surgery performed at The University of Texas M. D. Anderson Cancer Center between 1990 and 2000. Immunohistochemistry studies were performed by using the immunoperoxidase technique against primary antibodies (ER, PR, and AR). Results. ERs, PRs, and ARs were differently expressed in different histotypes of ovarian cancer: ERs were expressed in 77.3% of all cases but more highly expressed in serous and endometrioid types; PRs were expressed in 26.2% of all cases but most highly expressed in the endometrioid type < 64.2%; and ARs were expressed in 43.7% of all cases but were most highly expressed in serous (47.5%) carcinomas. Of particular importance, the expression of PRs, but not ERs or ARs, was associated with better survival (P < 0.0001) in univariate and multivariate analyses. Conclusions. The PR is an independent marker, with its overexpression associated with a favorable prognosis in women with ovarian cancer.

Original languageEnglish (US)
Pages (from-to)671-677
Number of pages7
JournalGynecologic Oncology
Volume96
Issue number3
DOIs
StatePublished - Mar 2005
Externally publishedYes

Fingerprint

Progesterone Receptors
Ovarian Neoplasms
Carcinoma
Progesterone
Neoplasms
Androgen Receptors
Gonadal Steroid Hormones
Endometrial Neoplasms
Immunoenzyme Techniques
Estrogen Receptors
Androgens
Histology
Estrogens
Carcinogenesis
Multivariate Analysis
Immunohistochemistry
Breast Neoplasms
Survival
Antibodies

Keywords

  • Estrogen
  • Ovarian cancer
  • Progesterone

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. / Lee, Peng; Rosen, Daniel G.; Zhu, Changcheng; Silva, Elvio G.; Liu, Jinsong.

In: Gynecologic Oncology, Vol. 96, No. 3, 03.2005, p. 671-677.

Research output: Contribution to journalArticle

Lee, Peng ; Rosen, Daniel G. ; Zhu, Changcheng ; Silva, Elvio G. ; Liu, Jinsong. / Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. In: Gynecologic Oncology. 2005 ; Vol. 96, No. 3. pp. 671-677.
@article{fe0967142225413f9a17a8138d57bb24,
title = "Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer",
abstract = "Objective. Receptors for estrogen (ER), progesterone (PR), or androgen (AR) are predictive and prognostic markers of malignancy of multiple endocrine organs, including endometrial and breast cancer. However, the role of ERs, PRs, or ARs in the carcinogenesis of ovarian cancer, another sex hormone-dependent malignancy, is still controversial despite numerous studies that have attempted to determine their role. The disagreement in the findings may result from the fact that the numbers of tumor samples in studies have been small and that different immunohistochemical methods have been used that can introduce variation in the scoring of the histology. We therefore examined the pattern of expression of ERs, PRs, and ARs in a large number of samples of primary ovarian carcinoma by using a tissue microarray technique. Methods. We constructed a tissue microarray with 322 samples of primary ovarian carcinoma obtained at surgery performed at The University of Texas M. D. Anderson Cancer Center between 1990 and 2000. Immunohistochemistry studies were performed by using the immunoperoxidase technique against primary antibodies (ER, PR, and AR). Results. ERs, PRs, and ARs were differently expressed in different histotypes of ovarian cancer: ERs were expressed in 77.3{\%} of all cases but more highly expressed in serous and endometrioid types; PRs were expressed in 26.2{\%} of all cases but most highly expressed in the endometrioid type < 64.2{\%}; and ARs were expressed in 43.7{\%} of all cases but were most highly expressed in serous (47.5{\%}) carcinomas. Of particular importance, the expression of PRs, but not ERs or ARs, was associated with better survival (P < 0.0001) in univariate and multivariate analyses. Conclusions. The PR is an independent marker, with its overexpression associated with a favorable prognosis in women with ovarian cancer.",
keywords = "Estrogen, Ovarian cancer, Progesterone",
author = "Peng Lee and Rosen, {Daniel G.} and Changcheng Zhu and Silva, {Elvio G.} and Jinsong Liu",
year = "2005",
month = "3",
doi = "10.1016/j.ygyno.2004.11.010",
language = "English (US)",
volume = "96",
pages = "671--677",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer

AU - Lee, Peng

AU - Rosen, Daniel G.

AU - Zhu, Changcheng

AU - Silva, Elvio G.

AU - Liu, Jinsong

PY - 2005/3

Y1 - 2005/3

N2 - Objective. Receptors for estrogen (ER), progesterone (PR), or androgen (AR) are predictive and prognostic markers of malignancy of multiple endocrine organs, including endometrial and breast cancer. However, the role of ERs, PRs, or ARs in the carcinogenesis of ovarian cancer, another sex hormone-dependent malignancy, is still controversial despite numerous studies that have attempted to determine their role. The disagreement in the findings may result from the fact that the numbers of tumor samples in studies have been small and that different immunohistochemical methods have been used that can introduce variation in the scoring of the histology. We therefore examined the pattern of expression of ERs, PRs, and ARs in a large number of samples of primary ovarian carcinoma by using a tissue microarray technique. Methods. We constructed a tissue microarray with 322 samples of primary ovarian carcinoma obtained at surgery performed at The University of Texas M. D. Anderson Cancer Center between 1990 and 2000. Immunohistochemistry studies were performed by using the immunoperoxidase technique against primary antibodies (ER, PR, and AR). Results. ERs, PRs, and ARs were differently expressed in different histotypes of ovarian cancer: ERs were expressed in 77.3% of all cases but more highly expressed in serous and endometrioid types; PRs were expressed in 26.2% of all cases but most highly expressed in the endometrioid type < 64.2%; and ARs were expressed in 43.7% of all cases but were most highly expressed in serous (47.5%) carcinomas. Of particular importance, the expression of PRs, but not ERs or ARs, was associated with better survival (P < 0.0001) in univariate and multivariate analyses. Conclusions. The PR is an independent marker, with its overexpression associated with a favorable prognosis in women with ovarian cancer.

AB - Objective. Receptors for estrogen (ER), progesterone (PR), or androgen (AR) are predictive and prognostic markers of malignancy of multiple endocrine organs, including endometrial and breast cancer. However, the role of ERs, PRs, or ARs in the carcinogenesis of ovarian cancer, another sex hormone-dependent malignancy, is still controversial despite numerous studies that have attempted to determine their role. The disagreement in the findings may result from the fact that the numbers of tumor samples in studies have been small and that different immunohistochemical methods have been used that can introduce variation in the scoring of the histology. We therefore examined the pattern of expression of ERs, PRs, and ARs in a large number of samples of primary ovarian carcinoma by using a tissue microarray technique. Methods. We constructed a tissue microarray with 322 samples of primary ovarian carcinoma obtained at surgery performed at The University of Texas M. D. Anderson Cancer Center between 1990 and 2000. Immunohistochemistry studies were performed by using the immunoperoxidase technique against primary antibodies (ER, PR, and AR). Results. ERs, PRs, and ARs were differently expressed in different histotypes of ovarian cancer: ERs were expressed in 77.3% of all cases but more highly expressed in serous and endometrioid types; PRs were expressed in 26.2% of all cases but most highly expressed in the endometrioid type < 64.2%; and ARs were expressed in 43.7% of all cases but were most highly expressed in serous (47.5%) carcinomas. Of particular importance, the expression of PRs, but not ERs or ARs, was associated with better survival (P < 0.0001) in univariate and multivariate analyses. Conclusions. The PR is an independent marker, with its overexpression associated with a favorable prognosis in women with ovarian cancer.

KW - Estrogen

KW - Ovarian cancer

KW - Progesterone

UR - http://www.scopus.com/inward/record.url?scp=13844299310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13844299310&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2004.11.010

DO - 10.1016/j.ygyno.2004.11.010

M3 - Article

VL - 96

SP - 671

EP - 677

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -